ReGrow Medical

Hair Loss Treatment in 2026: What Works, What's Unapproved, and How to Choose

Written by ReGrow Medical Editorial Team.

Medically reviewed by Dr. Amiel Moshfegh, M.D.

Published . Updated .

The short answer

For diagnosed pattern hair loss, topical minoxidil and oral finasteride for eligible men have established FDA-approved uses. Oral minoxidil is used off-label; compounded topical finasteride is not FDA approved. PRP, laser devices, and transplantation have different roles and evidence. Start with the cause, then compare benefits, risks, maintenance, and what each option can realistically change.

Choosing a treatment in 2026 means sorting through very different kinds of claims. A prescription is not necessarily an FDA-approved use. A device clearance is not a drug approval. And a large number of satisfied customers is not the same as a controlled trial showing hair growth.

This guide focuses on adult pattern hair loss. It explains the established options, a major 2026 topical-finasteride study, and the questions that help turn a treatment list into a workable plan. It is general education, not a personal prescription.

First, confirm what is causing the loss

A widening part, a receding hairline, and sudden shedding are not diagnoses. A clinician may review your timeline, health changes, medications, family history, and scalp findings. Testing is selected when the examination suggests a reason; buying a broad supplement panel is not a substitute for an assessment.

Sudden patches, pain, burning, inflammation, or scar-like changes deserve prompt medical evaluation. A dermatologist may need to investigate a condition that a cosmetic treatment would miss. The American Academy of Dermatology explains this diagnostic approach. For help choosing a provider, read our dermatologist and trichologist guide.

Hair loss treatments in 2026: compare the role and the evidence

These categories describe different regulatory and clinical questions. “Off-label” means an approved medicine is prescribed outside its approved indication or other labeling. A compounded formulation has not itself been FDA approved. Neither term, by itself, settles whether an option is appropriate for you.

Options for adult pattern hair loss—not a ranking of treatments
OptionU.S. status / roleMain question to ask
Topical minoxidilFDA-approved products for pattern hair loss; formulation-specific directions.Can I use the appropriate product consistently and tolerate it?
Oral finasteride 1 mgFDA approved for male pattern hair loss in men.Do the potential benefits fit my medical history and risk preferences?
Compounded topical finasterideNo FDA-approved topical formulation; subject of an April 2025 FDA risk alert.Why this formulation, and how will systemic effects and transfer exposure be addressed?
Low-dose oral minoxidilOff-label prescription use for hair loss.What assessment and monitoring do I need?
PRPProcedure studied for pattern hair loss; studies and protocols vary.What evidence supports the proposed protocol and ongoing cost?
Low-level laser devicesSome devices have FDA clearance for specified populations.Does the exact device's indication fit me?
FUE hair transplantationSurgery that redistributes suitable donor follicles.Is my diagnosis, donor supply, and long-term plan suitable?

A treatment being discussed here does not mean ReGrow offers every option or recommends it for every patient.

The 2026 topical-finasteride study: a large dataset with important gaps

On January 22, 2026, Yu and colleagues published a retrospective analysis in JMIR Dermatology. It examined 638,629 adult men prescribed compounded topical finasteride combined with minoxidil through the Hims & Hers telehealth platform between April 2021 and April 2025.

The headline sample is large. The follow-up sample is a different number: 151,352 men, or 23.7%, answered the optional follow-up assessment, scheduled around 130 days. That distinction matters before interpreting the results.

Read the denominator before the percentage

638,629
Men prescribed the compounded combination in the dataset.
151,352 / 23.7%
Men who completed the optional follow-up.
80.4%
Of respondents reported satisfaction: 121,615 of 151,352.
2.7%
Of respondents reported side effects: 4,034 of 151,352.

Those percentages do not describe the outcomes of everyone prescribed treatment. Satisfaction is also not a standardized measurement of regrowth. The study did not establish that the combination produced a particular improvement in hair count, or that topical finasteride was responsible for any improvement.

What the study can—and cannot—tell you

  • It captures patient reports in ordinary prescribing practice. That is useful context beyond a small trial, but prescriptions do not prove consistent use.
  • There was no control group. It cannot establish causation or reliably compare the combination with oral finasteride, minoxidil alone, or no treatment.
  • Most patients did not answer follow-up. Nonrespondents may differ from respondents. The direction and size of that bias cannot simply be assumed.
  • Side effects were self-reported. Problems managed outside the platform, later events, and incomplete reporting could be missed. A low reported proportion cannot rule out uncommon or persistent harms.
  • The findings concern specific combination products. They should not be generalized to every concentration, formulation, dispensing practice, or to women.
  • The study has commercial ties. Hims & Hers funded it; four authors were employees and two were advisers. That does not automatically invalidate the work, but readers should know who produced it.

The defensible conclusion is narrower than “proven safe and effective”: many respondents were satisfied, and a minority reported side effects in this particular dataset. The study leaves substantial uncertainty about outcomes among nonrespondents and comparative benefits or harms. Read the original study, including its limitations and disclosures.

How this fits with the FDA's April 22, 2025 alert

The FDA alert predates the paper. It states that there is no FDA-approved topical finasteride formulation, that skin absorption into the bloodstream is expected, and that reports included systemic symptoms—some described as continuing after discontinuation. Local irritation and unintended transfer to other people are additional concerns.

The alert and the study answer different questions. Adverse-event reports identify potential safety concerns; they do not establish how often a problem occurs. An optional satisfaction survey cannot dismiss those concerns. Neither source justifies a promise that a topical product has no systemic risk. Pregnancy-related exposure precautions need an explicit discussion with the prescriber.

Before using a compounded product, ask why it is being recommended, what alternatives exist, which pharmacy prepares it, and what to do if symptoms occur. Read the FDA alert.

Minoxidil and finasteride: established options, different decisions

Topical minoxidil

Topical minoxidil can support growth in appropriate patients with pattern hair loss. Product labels differ by formulation and intended user; the men's 5% solution directions are not universal instructions for every foam, solution, or patient. Apply the relevant label and clinician's advice, not a routine copied from social media.

Response takes time and continued use is generally needed to maintain benefit. Scalp irritation and unwanted hair growth can occur. The label advises medical attention for symptoms such as chest pain, rapid heartbeat, faintness, or swelling. More product is not a shortcut to better results. FDA men's 5% solution labeling.

Oral finasteride

Oral finasteride 1 mg is approved for male pattern hair loss in men. The prescribing discussion should cover potential sexual adverse effects, mood concerns, pregnancy precautions, and its effect on PSA test interpretation. The 2022 Propecia label includes postmarketing reports of sexual dysfunction continuing after discontinuation and depression or suicidal ideation; such reports do not establish an individual patient's likelihood of experiencing them.

Benefit is assessed over months, and continued treatment is generally needed. It is not indicated for women, and people who are pregnant or may become pregnant should not handle crushed or broken tablets. FDA Propecia prescribing information.

For the relationship between medication and surgery, read minoxidil and finasteride after a hair transplant. If you are weighing the long-term commitment, see what happens when minoxidil or finasteride is stopped.

Low-dose oral minoxidil

Oral minoxidil is an off-label hair-loss treatment, not simply topical minoxidil in a more convenient form. Its approved use is for certain patients with high blood pressure. A prescriber must consider medical history, interacting medications, and monitoring. Potential problems include unwanted hair growth, fluid retention, and cardiovascular effects; oral minoxidil carries important heart-related warnings.

The international JAMA Dermatology consensus published in 2025 provides expert guidance on assessment and prescribing while acknowledging evidence gaps. Expert consensus is not a new FDA approval. See the consensus and MedlinePlus drug information. For surgery-specific questions, use our oral minoxidil before and after hair transplant guide.

Where PRP fits

Platelet-rich plasma uses a preparation from the patient's blood, injected into the scalp. A 2024 systematic review included eight randomized trials and one cohort study, with 291 participants. Several studies reported improvements, but most had moderate risk of bias. That supports a cautious discussion—not a universal response promise.

Ask how the clinic prepares PRP, what outcome will be measured, how many visits are proposed, and what maintenance could cost. A study of one protocol does not validate every package sold under the same name. Read the systematic review and our PRP evidence guide.

Laser caps and combs: check the exact device

Some low-level laser devices have FDA clearance for specified pattern-loss populations. That is a device-specific regulatory determination, not blanket approval of every red-light product. For example, the iGrow-II clearance document names particular male pattern-loss classifications and skin phototypes.

Before buying a cap or comb, ask for its clearance number, intended-use population, instructions, and evidence for that model. Compare the time commitment and total cost as well as the purchase price. Evidence for one device cannot establish that a different wavelength, design, or schedule delivers the same result. The AAD describes promising but variable responses in its treatment overview.

Treatment for women needs its own assessment

The 2026 topical-finasteride dataset studied men; it cannot establish outcomes in women. Female pattern loss may overlap with other causes of shedding. Pregnancy plans, breastfeeding, medical history, and scalp findings affect the available choices.

Topical minoxidil has approved products for female pattern loss. Other prescriptions may be considered off-label by an appropriate clinician. The AAD advises avoiding minoxidil during pregnancy, pregnancy planning, and breastfeeding. Diffuse thinning can also limit suitable donor hair for surgery. Read the AAD guidance, our guide to hair loss in women, and women's transplant candidacy guide.

When a hair transplant enters the conversation

FUE moves suitable donor follicles to selected areas; it does not create an unlimited supply or stop the surrounding native hair from thinning. An examination should establish the diagnosis, scalp health, donor quality, and how future loss could affect the design. Inflammatory conditions can resemble pattern loss and may make surgery inappropriate while active. Preoperative assessment literature explains why these distinctions matter.

For someone considering surgery, the useful question is how preservation and restored coverage fit together over time. A transplant is not automatically the next step after a disappointing product trial. See hair transplant candidacy and FUE at ReGrow Medical.

Six questions to bring to a consultation

  1. What is my diagnosis? Ask what supports it and whether anything needs investigation before cosmetic treatment.
  2. What outcome are we aiming for? Less shedding, preservation, visible regrowth, and surgically restored coverage are different goals.
  3. What evidence applies to someone like me? Ask about the population, formulation, comparison group, follow-up, and who funded the study.
  4. What are the meaningful risks? Include medical history, other medicines, pregnancy or transfer exposure, and a clear contact plan for symptoms.
  5. How will we judge progress? Agree on follow-up and consistent photographs before starting, rather than judging every change in bathroom lighting.
  6. Can I maintain the plan? Discuss the routine, appointments, ongoing cost, and alternatives if it is not tolerable or practical.

Taking these questions to a visit is more useful than arriving with a fixed treatment order. Ask the clinician to explain what would change their recommendation. An uncertain diagnosis, an unacceptable adverse effect, or an unsustainable routine can each call for a different next step.

Considering a consultation in Los Angeles?

ReGrow Medical can review your restoration goals, history, scalp, and donor area. Our Los Angeles hair loss consultation page explains what to bring and how to book. A consultation may identify the need for dermatologic evaluation before a restoration plan.

Frequently asked questions

What hair loss treatments are FDA approved in the United States?

Topical minoxidil products have approved uses for pattern hair loss, with directions that differ by formulation and patient population. Oral finasteride 1 mg is approved for male pattern hair loss in men. This guide addresses pattern hair loss; other diagnoses have different treatments. Some laser devices are FDA cleared, a different regulatory pathway.

Is topical finasteride FDA approved in 2026?

No. There is no FDA-approved topical finasteride product in the United States. The FDA issued a risk alert about compounded topical finasteride on April 22, 2025. A prescription or a large observational study does not change the approval status of a compounded product.

Does the 2026 study prove topical finasteride is safe?

No. The study analyzed prescriptions for 638,629 men, but only 151,352, or 23.7%, completed follow-up. Among those respondents, 80.4% were satisfied and 2.7% reported side effects. These are self-reported outcomes from a retrospective study without a control group, not proof of safety or efficacy.

Is oral minoxidil approved for hair loss?

Oral minoxidil is used off-label for hair loss. Its approved use is for certain patients with high blood pressure. A prescriber should assess suitability, risks, other medications, and monitoring; it is not interchangeable with a topical product.

Can treatment work without a hair transplant?

Yes, depending on the diagnosis and follicles that remain. Medical treatment may help preserve or improve existing hair, and some temporary shedding improves when its cause is addressed. Surgery has a different role: relocating suitable donor follicles to selected areas.

Do I have to keep using hair loss medication?

Maintaining the benefits of minoxidil or finasteride generally requires continued treatment. Before starting, discuss the ongoing commitment and what to do if side effects occur. Do not use a general article as instructions to start, stop, or switch a prescribed medication.

Does a hair transplant stop future hair loss?

No. A hair transplant redistributes existing donor follicles. Native hair can continue to thin, so surgical planning should account for the likely course of loss, donor limitations, and whether medical treatment is appropriate.

Where should I start if I am comparing treatment in Los Angeles?

Start with a medical assessment of the cause. ReGrow Medical offers restoration consultations that review your history, scalp, donor area, and goals. Sudden, patchy, painful, inflamed, or unexplained loss may need dermatologic evaluation before a cosmetic restoration plan.